Trial abstract · §3
HEX-PH1-GH — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Growth-hormone response to a single dose | Marked growth-hormone release with attenuation on repeated administration | Low |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Hexarelin from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Cortisol elevation | — | — | A consistent finding and the principal pharmacological objection to this compound |
| Prolactin elevation | — | — | Consistent |
| Flushing | — | — | Reported |
| Transient hunger | — | — | Marked; more pronounced than with selective secretagogues |
| Injection-site reaction | — | — | Reported |
| Somnolence | — | — | Reported |
Compound Evidence Institute · CEI-TR-0104/3 · https://compoundevidence.com/trials/hex-ph1-gh/results/ · retrieved 30 July 2026